Peapod Lane Capital LLC Takes Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Peapod Lane Capital LLC purchased a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 166,843 shares of the company’s stock, valued at approximately $1,660,000. Kodiak Sciences makes up 1.6% of Peapod Lane Capital LLC’s portfolio, making the stock its 26th biggest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KOD. State Street Corp grew its holdings in shares of Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after purchasing an additional 14,711 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after purchasing an additional 12,783 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Kodiak Sciences in the 3rd quarter valued at about $751,000. FMR LLC grew its stake in Kodiak Sciences by 26.4% during the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after buying an additional 41,987 shares during the last quarter. Finally, Barclays PLC increased its position in Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after buying an additional 31,527 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Trading Down 6.6 %

Shares of KOD stock opened at $4.99 on Thursday. The company has a market capitalization of $262.57 million, a P/E ratio of -1.37 and a beta of 2.06. The business’s 50 day moving average is $8.08 and its two-hundred day moving average is $5.13. Kodiak Sciences Inc. has a twelve month low of $2.18 and a twelve month high of $11.60.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KOD shares. HC Wainwright reissued a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a report on Friday, November 15th. Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Monday, December 9th. Finally, Barclays raised their price objective on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Friday, November 15th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.